TherapeuticsMD Past Earnings Performance
Past criteria checks 0/6
TherapeuticsMD's earnings have been declining at an average annual rate of -10.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 39.1% per year.
Key information
-10.2%
Earnings growth rate
1.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 39.1% |
| Return on equity | n/a |
| Net Margin | -29.5% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How TherapeuticsMD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 92 | -27 | 174 | 6 |
| 31 Mar 22 | 86 | -182 | 185 | 6 |
| 31 Dec 21 | 87 | -172 | 188 | 7 |
| 30 Sep 21 | 91 | -172 | 201 | 8 |
| 30 Jun 21 | 85 | -157 | 182 | 8 |
| 31 Mar 21 | 72 | -166 | 178 | 9 |
| 31 Dec 20 | 65 | -184 | 193 | 10 |
| 30 Sep 20 | 58 | -191 | 198 | 12 |
| 30 Jun 20 | 63 | -190 | 204 | 15 |
| 31 Mar 20 | 58 | -193 | 196 | 17 |
| 31 Dec 19 | 50 | -176 | 175 | 20 |
| 30 Sep 19 | 39 | -166 | 157 | 22 |
| 30 Jun 19 | 19 | -170 | 142 | 25 |
| 31 Mar 19 | 16 | -148 | 130 | 27 |
| 31 Dec 18 | 16 | -133 | 116 | 27 |
| 30 Sep 18 | 15 | -115 | 95 | 32 |
| 30 Jun 18 | 16 | -94 | 76 | 31 |
| 31 Mar 18 | 17 | -80 | 62 | 33 |
| 31 Dec 17 | 17 | -77 | 58 | 34 |
| 30 Sep 17 | 17 | -78 | 60 | 33 |
| 30 Jun 17 | 18 | -89 | 63 | 41 |
| 31 Mar 17 | 18 | -90 | 59 | 47 |
| 31 Dec 16 | 19 | -90 | 51 | 54 |
| 30 Sep 16 | 20 | -85 | 44 | 57 |
| 30 Jun 16 | 20 | -79 | 36 | 59 |
| 31 Mar 16 | 21 | -85 | 32 | 69 |
| 31 Dec 15 | 20 | -85 | 29 | 72 |
Quality Earnings: 29TA is currently unprofitable.
Growing Profit Margin: 29TA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 29TA is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 29TA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 29TA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 29TA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.